Lung Cancer Clinical Trial

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

Summary

The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof
No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy
Evidence of measurable disease by radiographic technique
Male or Female, 18 years or older
ECOG performance status of 0 or 1
Resolution of all acute toxicities of prior therapies
Adequate organ function

Exclusion Criteria:

Major surgery or radiation therapy within 4 weeks
Severe hemorrhage within 4 weeks
Previous treatment with anti-angiogenesis agents
Diagnosis of second malignancy within last five 5 years
History of or known brain metastases, spinal cord compression, or carcinomatous meningitis
Known HIV
Serious acute or chronic illness
Current treatment on another clinical trial
Pregnant or breastfeeding

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

111

Study ID:

NCT00092001

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Pfizer Investigational Site
Baltimore Maryland, 21231, United States
Pfizer Investigational Site
St. Louis Missouri, 63110, United States
Pfizer Investigational Site
St. Louis Missouri, 63110, United States
Pfizer Investigational Site
St. Peters Missouri, 63376, United States
Pfizer Investigational Site
Chapel Hill North Carolina, 27599, United States
Pfizer Investigational Site
Clinton North Carolina, 28382, United States
Pfizer Investigational Site
Goldsboro North Carolina, 27534, United States
Pfizer Investigational Site
Pollocksville North Carolina, 28573, United States
Pfizer Investigational Site
Wilson North Carolina, 27893, United States
Pfizer Investigational Site
Pittsburgh Pennsylvania, 15232, United States
Pfizer Investigational Site
Charlottesville Virginia, 22908, United States
Pfizer Investigational Site
Orbassano (Torino) , 10043, Italy
Pfizer Investigational Site
Badalona Barcelona, 08916, Spain
Pfizer Investigational Site
Barcelona , 08025, Spain

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

111

Study ID:

NCT00092001

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider